Article Text

Download PDFPDF
Sclerosing skin disorders in association with multiple sclerosis. Coincidence, underlying autoimmune pathology or interferon induced?
  1. T Hügle,
  2. S Gratzl,
  3. T Daikeler,
  4. D Frey,
  5. A Tyndall,
  6. U A Walker
  1. Felix Platter Spital, Basel University Department of Rheumatology, Switzerland
  1. Ulrich A Walker, Department of Rheumatology, Felix Platter Spital, Burgfelderstrasse 101, Basel 4012, Switzerland; ulrich.walker{at}


Objectives: To describe and analyse the manifestation of sclerosing skin disorders in patients with multiple sclerosis (MS).

Case reports: We describe three patients with relapsing-remitting MS who developed skin sclerosis while receiving interferon (IFN)-β treatment and review nine further cases of systemic sclerosis (SSc) in MS from the literature. Of all 12 patients reported, eight had limited cutaneous SSc, three had diffuse cutaneous SSc and one patient had an antisynthetase syndrome. Localised scleroderma such as morphoea was not described. The mean age at diagnosis was 25.2 years for MS (range 12 to 51) and 38.3 years for SSc (range 16 to 66). Eleven patients developed SSc after the onset of MS and manifested with skin sclerosis after a mean of 14.9 years (range 1 to 45). In five patients IFN-β was commenced before the development of skin sclerosis (mean 4.6 years, range 1 to 8 years). There was no relationship between the onset of skin sclerosis and MS activity. With the exception of one individual, all patients had antinuclear antibodies.

Conclusions: Sclerosing skin disorders may develop in the course of MS. The relatively early age of SSc onset in patients with MS suggests a genetic predisposition and/or an IFN-associated trigger.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: None.

  • Patient consent: Obtained.